ZAI LAB LTD0000006 (1ZLB) - Net Assets
Based on the latest financial reports, ZAI LAB LTD0000006 (1ZLB) has net assets worth €715.50 Million EUR (≈ $836.49 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.17 Billion ≈ $1.37 Billion USD) and total liabilities (€456.88 Million ≈ $534.15 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of ZAI LAB LTD0000006 to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €715.50 Million |
| % of Total Assets | 61.03% |
| Annual Growth Rate | -15.14% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 12.12 |
ZAI LAB LTD0000006 - Net Assets Trend (2021–2025)
This chart illustrates how ZAI LAB LTD0000006's net assets have evolved over time, based on quarterly financial data. Also explore ZAI LAB LTD0000006 assets under control for the complete picture of this company's asset base.
Annual Net Assets for ZAI LAB LTD0000006 (2021–2025)
The table below shows the annual net assets of ZAI LAB LTD0000006 from 2021 to 2025. For live valuation and market cap data, see market cap of ZAI LAB LTD0000006.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €715.50 Million ≈ $836.49 Million |
-14.91% |
| 2024-12-31 | €840.90 Million ≈ $983.10 Million |
+5.62% |
| 2023-12-31 | €796.12 Million ≈ $930.75 Million |
-23.86% |
| 2022-12-31 | €1.05 Billion ≈ $1.22 Billion |
-24.23% |
| 2021-12-31 | €1.38 Billion ≈ $1.61 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ZAI LAB LTD0000006's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 121054600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €3.34 Billion | 467.38% |
| Total Equity | €715.50 Million | 100.00% |
ZAI LAB LTD0000006 Competitors by Market Cap
The table below lists competitors of ZAI LAB LTD0000006 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Suzhou TZTEK Technology Co Ltd
SHG:688003
|
$2.05 Billion |
|
Electra Ltd
TA:ELTR
|
$2.05 Billion |
|
HENSOLDT AG UNSP. ADS
F:HAG0
|
$2.05 Billion |
|
Rendong Holdings Co Ltd
SHE:002647
|
$2.05 Billion |
|
Central China Securities Co Ltd
SHG:601375
|
$2.05 Billion |
|
Perdoceo Education Corp
NASDAQ:PRDO
|
$2.05 Billion |
|
Penn National Gaming Inc
NASDAQ:PENN
|
$2.05 Billion |
|
Oesterr. Post AG
VI:POST
|
$2.05 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ZAI LAB LTD0000006's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 840,898,000 to 715,500,000, a change of -125,398,000 (-14.9%).
- Net loss of 175,537,000 reduced equity.
- Other factors increased equity by 50,139,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-175.54 Million | -24.53% |
| Other Changes | €50.14 Million | +7.01% |
| Total Change | €- | -14.91% |
Book Value vs Market Value Analysis
This analysis compares ZAI LAB LTD0000006's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.78x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.25x to 2.78x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €1.45 | €1.80 | x |
| 2022-12-31 | €1.09 | €1.80 | x |
| 2023-12-31 | €0.82 | €1.80 | x |
| 2024-12-31 | €0.78 | €1.80 | x |
| 2025-12-31 | €0.65 | €1.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ZAI LAB LTD0000006 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -38.15%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.64x
- Recent ROE (-24.53%) is above the historical average (-38.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -51.05% | -488.16% | 0.09x | 1.17x | €-842.47 Million |
| 2022 | -42.40% | -206.14% | 0.18x | 1.17x | €-547.85 Million |
| 2023 | -42.03% | -125.46% | 0.26x | 1.30x | €-414.23 Million |
| 2024 | -30.57% | -64.44% | 0.34x | 1.41x | €-341.19 Million |
| 2025 | -24.53% | -38.15% | 0.39x | 1.64x | €-247.09 Million |
Industry Comparison
This section compares ZAI LAB LTD0000006's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $622,769,703
- Average return on equity (ROE) among peers: -64.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ZAI LAB LTD0000006 (1ZLB) | €715.50 Million | -51.05% | 0.64x | $2.05 Billion |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-4.10 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $538.39 Million | -12.38% | 0.07x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $1.12 Billion |
| BioNTech SE (22UA) | $493.49 Million | -36.28% | 0.62x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.54 Billion | -12.40% | 0.05x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.56 Billion | -20.91% | 0.36x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-247.66K | 0.00% | 0.00x | $3.31 Million |
About ZAI LAB LTD0000006
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more